Artikel: Empagliflozin/linagliptin GudangMovies21 Rebahinxxi

    • Source: Empagliflozin/linagliptin

      • Empagliflozin/linagliptin, sold under the brand name Glyxambi, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes. It is a combination of empagliflozin and linagliptin. It is taken by mouth.
      The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections .
      It was approved for use in the United States in January 2015, for use in the European Union in November 2016, and for use in Australia in December 2016.


      Medical uses


      In the United States empagliflozin/linagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.
      In the European Union empagliflozin/linagliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus:

      to improve glycemic control when metformin and/or sulphonylurea (SU) and empagliflozin or linagliptin do not provide adequate glycemic control;
      when already being treated with the free combination of empagliflozin and linagliptin.


      Adverse effects


      The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections . The most serious side effects include ketoacidosis (high blood levels of acids called ‘ketoacids’), pancreatitis (inflammation of the pancreas), hypersensitivity (allergic reactions) and hypoglycaemia (low blood sugar levels).


      History


      The combination preparation was developed and is marketed by Boehringer Ingelheim and Eli Lilly and Company under the brand name Glyxambi.


      References




      Further reading


      Kim ES, Deeks ED (September 2015). "Empagliflozin/Linagliptin: A Review in Type 2 Diabetes". Drugs. 75 (13): 1547–57. doi:10.1007/s40265-015-0457-z. PMID 26323340. S2CID 27675087.

    Kata Kunci Pencarian:

    empagliflozin linagliptin patenempagliflozin linagliptinempagliflozin linagliptin 25 5 mgmetformin linagliptin dan empagliflozinempagliflozin linagliptin 10 5 mgempagliflozin linagliptin brand nameempagliflozin linagliptin 25 5 mg priceempagliflozin linagliptin usesempagliflozin linagliptin glyxambiempagliflozin linagliptin combinationSearch Results

    Artikel Terkait "empagliflozin linagliptin"

    Empagliflozin and linagliptin (oral route) - Mayo Clinic

    01 Jan 2025 · Empagliflozin and linagliptin is a combination medicine for type 2 diabetes and heart or blood vessel disease. It works by lowering blood sugar levels and preventing kidney …

    Empagliflozin/linagliptin - Wikipedia

    Empagliflozin/linagliptin, sold under the brand name Glyxambi, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes. It is a combination of empagliflozin and linagliptin. It is taken by mouth. The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections .

    Glyxambi (empagliflozin/linagliptin) - Uses, Side …

    21 Jul 2024 · What is Glyxambi used for? Glyxambi (empagliflozin/linagliptin) is commonly used for the following conditions. To help lower blood glucose (sugar) levels in people with type 2 diabetes.

    Trijardy XR (empagliflozin/linagliptin/metformin)

    24 Jul 2024 · Find patient medical information for Trijardy XR (empagliflozin/linagliptin/metformin) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings